Literature DB >> 12562038

Relationship between HAART adherence and adipose tissue alterations.

Adriana Ammassari1, Andrea Antinori, Alessandro Cozzi-Lepri, Maria Paola Trotta, Guglielmo Nasti, Anna Lisa Ridolfo, Francesco Mazzotta, Albert W Wu, Antonella d'Arminio Monforte, Massimo Galli.   

Abstract

Adipose tissue alterations (ATA), which are common among persons treated with highly active antiretroviral therapy (HAART), can have substantial psychologic repercussions, with a subsequent negative impact on the patient's quality of life and on HAART adherence. However, the cross-sectional nature of the studies precludes establishing the direction and causality of the relationship. The authors evaluated the longitudinal relationship between ATA and adherence to HAART. The analysis included all participants in the AdICoNA and the LipolCoNA substudies of the Italian Cohort Naive Antiretrovirals (ICoNA). Adherence was assessed using a 16-item self-administered questionnaire, which also included a question on self-perceived fat accumulation experienced during the past 4 weeks. ATA was diagnosed by physicians at enrollment and evaluated every 6 months thereafter. There were 207 patients, with a median age of 35 years; 73% were men; and 34% acquired HIV through injection drug use. At baseline, nonadherence was reported by 63% of participants, and ATA was self-perceived by 15% and clinically diagnosed in 25%. Using Cox regression analysis, patients with good adherence at baseline were more likely to develop ATA (RH = 2.58; 95% CI, 1.09-6.11) and developed it sooner. Self-perceived ATA at baseline was independently related to subsequent nonadherence (OR, 4.67; 95% CI, 1.01-22.4), but clinically diagnosed ATA was not (OR, 0.77; 95% CI, 0.37-1.61). Patients' adherence to HAART is a dynamic process that interacts with ATA. Better adherence is associated with a higher risk of subsequent occurrence of ATA, while patient-perceived onset of morphologic alterations can reduce adherence to antiretroviral therapy.

Entities:  

Mesh:

Year:  2002        PMID: 12562038     DOI: 10.1097/00126334-200212153-00011

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  45 in total

Review 1.  Management of the metabolic effects of HIV and HIV drugs.

Authors:  Todd T Brown; Marshall J Glesby
Journal:  Nat Rev Endocrinol       Date:  2011-09-20       Impact factor: 43.330

Review 2.  Considering metabolic issues when initiating HIV therapy.

Authors:  David Alain Wohl
Journal:  Curr HIV/AIDS Rep       Date:  2007-08       Impact factor: 5.071

3.  A perfect platform: combining contingency management with medications for drug abuse.

Authors:  Kathleen M Carroll; Bruce J Rounsaville
Journal:  Am J Drug Alcohol Abuse       Date:  2007       Impact factor: 3.829

4.  The effects of exercise training on quality of life in HAART-treated HIV-positive Rwandan subjects with body fat redistribution.

Authors:  Eugene Mutimura; Aimee Stewart; Nigel J Crowther; Kevin E Yarasheski; W Todd Cade
Journal:  Qual Life Res       Date:  2008-03-05       Impact factor: 4.147

5.  HIV-associated lipodystrophy syndrome: A review of clinical aspects.

Authors:  Jean-Guy Baril; Patrice Junod; Roger Leblanc; Harold Dion; Rachel Therrien; Franãois Laplante; Julian Falutz; Pierre Côté; Marie-Nicole Hébert; Richard Lalonde; Normand Lapointe; Dominic Lévesque; Lyse Pinault; Danielle Rouleau; Cécile Tremblay; Benoãt Trottier; Sylvie Trottier; Chris Tsoukas; Karl Weiss
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-07       Impact factor: 2.471

6.  Quality of life and body image in the assessment of psychological impact of lipodystrophy: validation of the Italian version of assessment of body change and distress questionnaire.

Authors:  G Guaraldi; G Orlando; R Murri; M Vandelli; M De Paola; B Beghetto; G Nardini; S Ciaffi; F Vichi; A W Wu
Journal:  Qual Life Res       Date:  2006-02       Impact factor: 4.147

7.  Mitochondrial oxidative phosphorylation protein levels in peripheral blood mononuclear cells correlate with levels in subcutaneous adipose tissue within samples differing by HIV and lipoatrophy status.

Authors:  Cecilia M Shikuma; Mariana Gerschenson; Dominic Chow; Daniel E Libutti; John H Willis; James Murray; Roderick A Capaldi; Michael Marusich
Journal:  AIDS Res Hum Retroviruses       Date:  2008-10       Impact factor: 2.205

8.  Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.

Authors:  Stephen Arpadi; Stephanie Shiau; Renate Strehlau; Leigh Martens; Faeezah Patel; Ashraf Coovadia; Elaine J Abrams; Louise Kuhn
Journal:  Arch Dis Child       Date:  2012-12-05       Impact factor: 3.791

Review 9.  HIV infection.

Authors:  Martin Talbot
Journal:  BMJ Clin Evid       Date:  2008-07-31

10.  The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters.

Authors:  Esteban Martinez; Fehmida Visnegarwala; Birgit Grund; Avis Thomas; Cynthia Gibert; Judith Shlay; Fraser Drummond; Daniel Pearce; Simon Edwards; Peter Reiss; Wafaa El-Sadr; Andrew Carr
Journal:  AIDS       Date:  2010-01-28       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.